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Exercise tolerance in chronic obstructive pulmonary disease (COPD) patients treated with oral 
aminophylline may be different from those treated with high-dose inhaled ipratropium bromide. The 
purpose of this study was to compare the effects of therapeutic doses of oral aminophylline with 
high-dose ipratropium bromide on spirometry and exercise tolerance. The study was conducted on three 
consecutive days in a double-blind, randomized, crossover fashion. Baseline studies obtained on each 
study day included vital signs, simple spirometry and a symptom-limited maximal cardiopulmonary 
stress test, after which patients received one of the following treatments on each day: Treatment 1, 
inhaled ipratropium (total dose of 144pg) with placebo tablets; Treatment 2, inhaled placebo with oral 
aminophylline (400 mg); Treatment 3, inhaled placebo and placebo tablets. Simple spirometry was 
repeated at 60 and 120 min after baseline. Vital signs and cardiopulmonary stress testing was repeated at 
120 min. 
Eighteen patients were enrolled in the study, and 17 of these completed the study. There was a 
significant (PcO.05) increase in both forced expiratory volume in 1 s (FEV,), from 0.75 (0.21) to 0.92 
(0.3), and forced vital capacity (FVC), from 1.8 (0.79) to 2.11 (0.84), with high-dose ipratropium despite 
prior P-agonist therapy. Lack of improvement in exercise capacity was noted with ipratropium despite 
improvement in spirometry. 
These results suggest that elderly patients with severe COPD may have exercise limitation that is 
not directly dependent on severity of airflow obstruction. Ipratropium bromide and aminophylline 
demonstrated no acute effects on exercise capacity. 
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Introduction 
The quaternary ammonium anti-cholinergic 
compound ipratropium bromide is commonly 
prescribed for patients with chronic obstructive 
pulmonary disease (COPD). In patients with 
stable COPD, inhalation of 3640,~g ipratro- 
pium has been shown to produce a larger 
improvement in forced expiratory volume in 1 s 
Received 18 March 1996 and accepted in revised form 
26 June 1996. 
(FEV,) with a greater peak response and dur- 
ation of action when compared to conventional 
P-agonist aerosols (l-3). Although the optimal 
dose of nebulized ipratropium in COPD has 
been found to be 0.4 mg (4) the dosage of 
ipratropium via metered dose inhaler has not 
been established in COPD. It has been suggested 
that ipratropium by metered dose inhaler in a 
higher than recommended (54108 pug) dose may 
be used as the first-line therapy for patients 
with COPD (5). At these higher doses, it has not 
been studied whether ipratropium results in 
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greater bronchodilation or improved exercise 
tolerance. 
High doses of inhaled ipratropium bromide in 
young, healthy adults resulted in slowing of 
heart rate and increased stroke volume at rest 
(6). In another study of patients with COPD, 
inhalation of 36pg ipratropium has been shown 
to be a more potent bronchodilator and free of 
cardiovascular side-effects when compared to 
therapeutic doses of theophylline which resulted 
in increased heart rate (7). Due to this difference 
in the degree of bronchodilatation and cardio- 
vascular response, the authors hypothesize that 
the exercise tolerance in patients treated with 
aminophylline can be different from those 
treated with ipratropium. The present study was 
designed to compare the effects of a therapeutic 
dose of oral aminophylline with high-dose 
inhaled ipratropium bromide on spirometry and 
exercise tolerance in elderly patients with severe 
COPD. A higher than the currently recom- 
mended dose of ipratropium, equivalent to the 
suggested maximum dose by Gross et al. (4), was 
administered. 
Methods 
Eighteen patients were selected from the authors’ 
outpatient population, and the study was 
approved by an Institutional Review Board and 
a Human Studies Subcommittee. Informed con- 
sent was obtained from each patient. All patients 
selected had COPD based on history, physical 
examination, chest roentgenogram and previous 
pulmonary function testing. All patients had a 
significant history of smoking. Three patients 
were smokers at the time of the study and the 
remaining patients were ex-smokers. Addition- 
ally, patients had stable COPD without any 
evidence of an acute exacerbation of their lung 
disease for 6 weeks prior to entry into the study. 
In all patients, FEV, was less than 1.5 I, total 
lung capacity (TLC) was greater than 80% pre- 
dicted, and carbon monoxide diffusing capacity 
(DLCO) was reduced (Table 1). Arterial blood 
gas data was obtained within 3 months prior to 
study entry. Patients had no personal or family 
history of asthma, and no blood or sputum 
eosinophilia. Two patients were on a daily dose 
of 5 mg prednisone. All 18 patients were using 
TABLE 1. Baseline patient data (n = 17) 
Parameter 
Age (years) 
FEY, (1) 
(Oh pred.) 
FVC (1) 
(% pred.) 
JILCO (% pred.) 
Smoking history (no. of patients) 
Current 
Ex-smoker 
f’a0, (mHg) 
PaCO, (mmHg) 
Mean (SD) 
66.76 (6.53) 
0.77 (0.27) 
26.06 (1057) 
1.96 (0.66) 
46,06 (15.09) 
28.07 (16.66) 
3 
14 
70.53 (13.07) 
43.06 (14.64) 
theophylline prior to study entry. None of the 
patients required supplemental oxygen. 
Study Design 
The study was conducted on three consecutive 
days in a double-blind, randomized, crossover 
fashion. A single-day trial of each medication 
was performed to measure the acute effects of 
aminophylline and ipratropium on spirometry 
and exercise tolerance. The patients were 
instructed to discontinue their aminophylline or 
theophylline products 48 h and their ipratro- 
pium bromide 12 h prior to entry in the study. 
Patients took all other medications as usual 
including oral and inhaled steroids and inhaled 
P-agonist agents. Additionally, patients were 
instructed to eat a light breakfast and refrain 
from consuming caffeine-containing beverages. 
Patients took their inhaled P-agonist 1 h prior 
to each testing period. Baseline studies obtained 
1 h after using the P-agonist aerosols included: 
(1) vital signs at rest; (2) simple spirometry with 
an FEV, and forced vital capacity (FVC); and 
(3) symptom-limited maximal cardiopulmonary 
stress test with continuous monitoring of the 
patients’ electrocardiogram, blood pressure, 
oxygen consumption, minute ventilation and 
oxygen saturation via pulse oximetry. Testing 
began at the same time each morning. 
After the baseline studies were completed, 
all patients received P-agonist inhaler followed 
by one of the treatments listed below, given at 
time 0. 
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TREATMENT 1 
(1) Inhaled ipratropium bromide 2 puffs every 
2 min for four doses (time 0, 2, 4, 6 min), for 
a total of 144pg. 
(2) Placebo tablets. 
TREATMENT 2 
(1) Placebo aerosol 2 puffs every 2 min for four 
doses (time 0, 2, 4, 6 min). 
(2) Short-acting oral aminophylline in a dose of 
400 mg. 
TREATMENT 3 
(1) Placebo aerosol 2 puffs every 2 min for four 
doses (time 0, 2, 4, 6 min). 
(2) Placebo tablets. 
The simple spirometry was repeated at 60 and 
120 min after time 0 (baseline). Resting vital 
signs and maximal symptom-limited cardiopul- 
monary stress test were repeated at 120 min after 
time 0. A serum theophylline level was obtained 
at 120 min after time 0. 
Testing Procedures 
Vital signs were measured with the patient seated 
in an upright posture in a relaxed position. 
Simple spirometry was obtained using a Spiro- 
mate AS-600 (Riko, Lake Success, NY, U.S.A.). 
For each determination of FVC and FEV,, 
the subjects performed at least three FVC 
manoeuvres, until the two best efforts were 
within 5% of each other. The best FVC and 
the best FEV, were then used for analysis. 
Symptom-limited exercise testing was performed 
on a variable-speed treadmill (Quinton, Seattle, 
WA, U.S.A.), and the work rate was increased 
every minute (Figure 1). Treadmill testing was 
selected because it is a familiar form of exercise 
that allows testing of most ambulatory patients. 
Patients were encouraged to walk on the tread- 
mill until they could go no longer. Cardiac 
rhythm and heart rate (HR) were recorded on a 
cardiac monitor (Hewlett Packard, Andover, 
MA, U.S.A.) connected to a strip chart recorder 
(Hewlett-Packard). Oxyhaemoglobin saturation 
(SaO,) was monitored with a pulse oximeter 
(Nellcor, Hayward, CA, U.S.A.). Breath-by- 
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FIG. 1. Exercise protocol demonstrating treadmill 
work changes. mph, miles per hour. 
breath collection of expired gases was accom- 
plished through a two-way, non-rebreathing 
valve, pneumotachograph, and 0, and CO, 
analysers (SensorMedics, Yorba Linda, CA, 
U.S.A.) were used to obtain oxygen consump- 
tion (VQ,), minUte ventilation (I/E), respir- 
atory exchange ratio WR), ventilatory 
equivalent for carbon dioxide ( I’E/~CO,) and 
oxygen pulse ( pO,/HR). Anaerobic threshold 
was determined using the v slope method. One 
patient was severely limited by his COPD and 
was unable to perform a treadmill test. In this 
patient, a 6-min walk test was performed, and 
SaO, was monitored. The tests were considered 
maximal if 85% pred. max PO,, FE or HR were 
achieved or there was persistent desaturation of 
4% or greater compared to the resting value. 
Analysis of Data 
Predicted normals for FEV, and FVC were 
calculated using Knudson criteria. Predicted 
maximum VE, HR and PO, were calculated 
using the following formulas: max 
FEV, x 35 (8) max HR=210-0.65 (age) &T 
i/0,=4.2 - (0.3 x age in years). Resting’ vital 
signs, FVC, FEV,, b’E, ti02, RER; tiE/i/GO, 
and j/O,/HR done before and after admin- 
istration of treatments on the three separate days 
were compared using analysis of variance with a 
SPSS statistical package. A one-way repeated 
measures ANOVA was used. Post-hoc signifi- 
cance testing for differences among means was 
carried out using a GT2 test. A P value of less 
than 0.05 was considered to be significant for the 
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differences among means. Data is reported as 
mean (standard deviation). 
Results 
Of the 18 patients enrolled, 17 completed the 
study. The remaining one patient complained of 
anterior chest pain during the first cardiopul- 
monary stress test, and the study was discon- 
tinued. His data was not included in the analysis. 
Results of spirometry on the three study days 
is shown in Fig. 2(a,b). The FEV, increased 
significantly (WO.05) with ipratropium at 
60 min, and there was no further significant 
change at 120 min. There was no significant 
increase in FEV, with theophylline. Functional 
vital capacity improved significantly with both 
ipratropium and theophylline at 60 min, and 
there was no further increase at 120 min. This 
increase in spirometry is over and above the 
improvement produced by P-agonists. 
Comparison of the parameters at peak exer- 
cise is shown in Table 2. Peak p02, maximum 
achieved i/E and HR, oxygen pulse and i/E/PO2 
did not differ significantly in the three treatment 
groups. All patients complained of dyspnoea as 
a reason for termination of the exercise test. 
None of the patients achieved anaerobic 
threshold. Seventeen patients completed two 
cardiopulmonary stress tests daily for three con- 
secutive days. All tests were discontinued at the 
patient’s request. Patients complained of severe 
shortness of breath as a reason for termination 
of exercise. Therefore, a total of 102 cardio- 
pulmonary stress tests were performed. In 72 
(71%) of these tests, patients achieved a FE max 
of 85% of predicted or greater. Eleven of 102 
(10.8%) tests had evidence of oxyhaemoglobin 
desaturation of greater than 4% from baseline. 
In four tests (3.9%) there was technical difficulty 
in obtaining SaOz. There was no significant 
difference in SaO, between the three treatments. 
There was no significant difference observed in 
the duration of exercise with the three different 
protocols. 
The resting HR with Treatment 2 (aminophyl- 
line) was significantly increased. There was 
no significant difference in resting HR at base- 
line and 120 min for ipratropium or placebo 
treatments. There was no change in HR max 
(a) * 
T 
60 
Time (mid 
120 
(b) 
* 
FIG. 2. Percentage change in forced expiratory 
volume in 1 s (a) (FEV,) and (b) forced vital 
capacity (FVC) at 60 and 120 min on the three 
study days compared with baseline on each day. 
*P<O.O5. Open bars, ipratropium; solid bars, 
placebo; hatched bars, theophylline. 
60 
Time (mid 
120 
during exercise (Table 2). Figure 3 demonstrates 
lack of change in peak PO, despite marked 
improvement in FEV, with ipratropium. 
The serum theophylline levels with Treatments 
1 and 3 remained below 2 ,ug ml - r . The mean 
theophylline level with Treatment 2 was 11.4 
(2.9) ,ug ml - i. All but one of the patients toler- 
ated high-dose ipratropium bromide. One 
patient who had history of doing poorly with 
ipratropium bromide inhalation prior to the 
study, complained of cough with Treatment 1 
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TABLE 2. Heart rate, minute ventilation, peak oxygen consumption and oxygen pulse on the three study days 
Rest Peak exercise 
(beatrrn ~ ‘) (1 rn? ‘) 
HR (beats min - ‘) PE (1 min - ‘) PO, (ml min - ‘) 0, pulse 
[“A pred.] [% pred.] [% pred.] (ml beat - ‘) 
Treatment 1 
Baseline 84.3 (13.3) 12.2 (2.9) 112.8 (15.3) 27.7 (12.0) 786.7 (368.5) 6.9 (3.0) 
C67.3 (9.3)] [105.4 (20.2)] i35.3 (17.2)] 
120-min 83.3 (14.3) 12.8 (4.0) 109.1 (915.2) 28.9 (11.7) 753.0 (78.6) 6.9 (2.8) 
[65.2 (8.6)] [91.1 (19.0)] [34.2 (3.7)] 
Treatment 2 
Baseline 84.2 (14.1) 13.0 (3.0) 108.6 (16.6) 26.8 (11~7) 742.9 (356.0) 6.9 (3.3) 
[65.2 (lO.l)] [lOO.O (27.3)] [33.9 (16.2)] 
120 min 90.4 (13.7)* 13.4 (3.6) 114.9 (11.9) 29.8 (14.8) 793.0 (93.0) 7.1 (3.2) 
[69.0 (6.9)] E103.1 (30.5)] L35.6 (4.4)] 
Treatment 3 
Baseline 84.8 (13.8) 12.3 (2.9) 111.9 (16.3) 27.7 (12.3) 680.0 (346.8) 6.2 (3.4) 
[66.9 (9.6)] [94.5 (18.6)] [33.1 (14.9)] 
120 min 83.3 (13.8) 12.2 (3.8) 107.7 (9.3) 28.4 (12.9) 780.0 (88.0) 7.3 (3.0) 
[64.5 (5.7)] 1105.0 (35.8)] r35.2 (4.0)] 
Treatment 1, placebo tablets, ipratropium bromide inhaler; Treatment 2, placebo inhaler, oral aminophylline; 
Treatment 3, placebo tablets, placebo inhaler. 
HR, heart rate; FE, minute ventilation; PO,, oxygen consumption. 
'"PCO.05. 
60 
:/: 2 
2 
2 
v 
$- 1.0 
lie g 
E 40 $ 
FEV, +O, max FEV, GO, max FEV, +Oio, max 
25 
Placebo Ipratropium Theophylline 
FIG. 3. Peak oxygen consumption (PO,) compared 
to forced expiratory volume in 1 s (FEV,) on the 
three study days compared with baseline on each 
day. "PcO.05. Solid bars, time 0; hatched bars, time 
120 min. 
and had worsening spirometry. All other patients 
had improvements in spirometry with Treatment 
1. No other adverse effects were noted. 
Discussion 
In this study, high-dose ipratropium bromide 
and therapeutic levels of aminophylline were 
compared in 17 patients with COPD. It was 
hypothesized that high-dose ipratropium bro- 
mide results in significant bronchodilation which 
may translate into increased exercise capacity as 
measured by oxygen consumption. The results 
indicate that despite significant improvement 
in spirometry with ipratropium bromide, there 
is no corresponding increase in exercise 
capacity. In addition, there was no significant 
difference in exercise response when compared to 
aminophylline. 
Inhaled ipratropium is an effective therapeutic 
agent in the management of stable COPD. 
Recently, it has been suggested that high-dose 
inhalation of ipratropium can be used to opti- 
mize its potential bronchodilating effects (5). 
Gross et al. (4) studied the dose-response of 
ipratropium as a nebulized solution in patients 
with stable COPD, and the optimal dose in this 
patient population was found to be 0.4 mg. 
These authors noted that the recommended dose 
of 40,~g via metered dose inhaler was found to 
be equivalent to about 0.1 mg of nebulized sol- 
ution, and significantly less than the optimal 
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dose of nebulized ipratropium (4). In view of 
these findings, the optimal dose of inhaled ipra- 
tropium via metered dose inhaler is 160,~g (8-9 
puffs). Based on this, the authors proceeded to 
evaluate the therapeutic efficacy and assess the 
side-effects of high-dose ipratropium, equivalent 
to about the optimal dose suggested by Gross 
et al. (4). In the present study, ipratropium at 
this dose resulted in additional bronchodilation 
over and above that seen with adrenergic agents. 
This is in agreement with a previous study using 
maximal P-agonist therapy, followed by atro- 
pine, where there was further bronchodilation 
with atropine over and above that produced by 
salbutamol (9). 
To the authors’ knowledge, this is the first 
study evaluating the effects of high-dose ipratro- 
pium on exercise tolerance in COPD patients. 
There was no difference in exercise tolerance 
between placebo, ipratropium and aminophyl- 
line. Previous studies using theophylline showed 
similar lack of improvement in exercise tolerance 
in COPD patients (10). The authors suggested 
that a lo-15% improvement in spirometry may 
be too small to result in significantly improved 
exercise tolerance. In the present patients, 
despite a much larger increase in resting pulmo- 
nary functions with ipratropium, no correspond- 
ing increase in peak oxygen consumption during 
exercise was found (Fig. 3). Similar findings were 
noted in a previous trial of ipratropium in 
chronic bronchitis patients, in whom there was a 
significant increase in FEV, and FVC, but no 
improvement in 12-min walking distance (11). In 
a study using salbutamol, there was no corre- 
lation between FEV, and exercise tolerance in 
COPD patients (12). Lack of correlation 
between exercise tolerance and FEV, has been 
noted in patients with COPD who were treated 
with inhaled metaproterenol, in whom exercise 
performance improved without significant 
improvement in spirometry (13). Such discrepan- 
cies between exercise capacity and bronchodi- 
lation can occur if some patients were maximally 
bronchodilated and others were not. This is 
unlikely in the present study patients since all 
but one patient showed marked improvement 
with ipratropium, suggesting that they were not 
maximally bronchodilated prior to admin- 
istration of study drug. A recent study demon- 
strated a decrease in resting oxygen consumption 
compared to baseline with ipratropium bromide 
(14). The authors hypothesized that the fall in 
PO, could indicate reduction in the work of 
breathing. Resting pulmonary functions may not 
be representative of the dynamic changes which 
occur during exercise in patients with COPD. In 
addition, relief of airway obstruction is not the 
only explanation for the effect on exercise. The 
exercise performance in COPD is limited by 
factors such as changes in lung mechanics, res- 
piratory muscle fatigue, altered pulmonary gas 
exchange, impaired perception of breathlessness, 
nutritional factors and presence of car pulmo- 
nale (15). Additionally, particularly in the 
age group of the present patients with chronic 
disease, deconditioning may play a role. 
The use of oral aminophylline in the present 
patients resulted in theophylline levels of 11.4 
(2.9) ,ug ml - ’ (moderate theophylline levels). 
Previous studies have suggested that because of a 
log-linear relationship between bronchodilation 
and blood level, little bronchodilator efficacy is 
lost by using a target therapeutic theophylline 
blood level of 10 (2) ,ug ml - ’ (16). Aminophyl- 
line treatment caused resting HR to increase 
significantly (Table 2) even at moderate theo- 
phylline levels. Previous studies have reported 
similar increases in resting HR in patients with 
COPD with the use of theophylline (17). Some 
authors report no increase in peak HR during 
exercise (18). Others noted that the peak HR 
during exercise significantly increases follow- 
ing aminophylline (19,20). The HR increase by 
aminophylline is thought to be mediated by 
catecholamines, and this effect may be obscured 
by the catecholamine outpouring during maxi- 
mal exercise (21). Different levels of theophyl- 
line, the level of exercise, and the fitness of the 
subjects are possible reasons for the differences 
between studies. 
In the present study, all patients were treated 
with P-agonist aerosol 1 h before administration 
of the study drug. P-agonist aerosol was admin- 
istered before the baseline exercise test to allow 
even the severely limited patients to participate 
in the exercise test. 
All of the patients in the present study had a 
significant smoking history, and all except one 
patient had improved spirometry with ipratro- 
pium. This is similar to the findings of Braun 
et al. who noted that ipratropium-responsive 
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patients had a greater smoking history (3) and 
lower FEV,. Only one of the present patients 
complained of cough with ipratropium, and 
although blinded to the study agent, this one 
patient correctly identified ipratropium when he 
received it. 
Another finding of the present study is that 
the baseline exercise data during maximal 
exercise performance was significantly different 
on the three study days. The mean coefficient of 
variation was greater than 15% for peak p02, 
peak $‘E and HR max. However, large spon- 
taneous variations in p02, FE and HR have 
been reported in patients with clinically stable 
severe COPD (22). 
In summary, the present patients had a 
marked increase in FVC and FEV, following 
administration of a relatively high dose of ipra- 
tropium, although they had been pre-treated 
with P-agonist aerosol. Since different dosages of 
ipratropium, i.e. high dose and conventional, 
were not tested, it is impossible to state whether 
the high dose was superior to the conventional. 
The authors were disappointed that the study 
patients showed no improvement in exercise 
capacity despite the marked improvement in 
pulmonary function. It is apparent that the 
elderly patients with severe COPD had exercise 
limitation that was not directly dependent on 
severity of airflow obstruction. One may wonder 
whether their exercise capacity would have 
improved further if their pulmonary function 
improvement was maintained for a long period. 
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